IHS Chemical Week

EnviroTech :: Regulatory :: Regulatory: Safety

FDA Issues Warning Letter to Eli Lilly API Plant

6:36 AM MST | February 24, 2010 | Deepti Ramesh

The U.S. FDA has issued a warning letter to Eli Lilly’s active pharmaceutical ingredients (API) facility at Carolina, Puerto Rico, for a significant deviation from the current good manufacturing practice (cGMP). An FDA inspection of the facility last July identified a significant deviation from cGMP requirements for the manufacture of APIs, and the deviation causes Eli Lilly’s API lyspro insulin zinc crystals, used in Humalog for diabetes treatment, to be adulterated, FDA says. The response from Eli Lilly, which the FDA received last August, lacks...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa